1. Federation of State Medical Boards. Guidelines for the Chronic Use of Opioid Analgesics. Available at https://www.fsmb.org/siteassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf. Last accessed August 12, 2022.
2. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
3. Kenen K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Medicine. 2012;6(2)e41.
4. International Narcotics Control Board. Narcotic Drugs, 2021: Estimated World Requirements for 2022. Available at https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2021/Narcotic_Drugs_Technical_Publication_2021.pdf. Last accessed August 12, 2022.
5. Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15:ES119-ES133.
6. Groenewald CB, Rabbitts JA, Gebert JT, Palermo TM. Trends in opioid prescriptions among children and adolescents in the United States: a nationally representative study from 1996 to 2012. Pain. 2016;157(5):1021-1027.
7. Miller NS, Greenfeld A. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. Am J Ther. 2004;11:26-32.
8. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: U.S. Department of Health and Human Services; 2007.
9. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
10. HHS.GOV/OPIOIDS. Opioid Crisis Statistics: Facts About Opioids. Available at https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#. Last accessed August 12, 2022.
11. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR. 2019;67(5152);1419-1427.
12. Dunham R, Hamauei S, Kante J. Memorandum: Recommendations for Addressing the Opioid Epidemic in Louisiana. Available at https://ldh.la.gov/assets/opioid/OpioidMemoLAExpertPanel.pdf. Last accessed August 12, 2022.
13. Louisiana Opioid Surveillance Initiative. Bureau of Health Informatics. Louisiana Department of Health. Opioid-Related Deaths in Louisiana: September 2020. Available at https://ldh.la.gov/assets/opioid/final2019DrugDeathFactsheet092220.pdf. Last accessed August 12, 2022.
14. Schieber LZ, Guy GP Jr, Seth P, et al. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006–2017. JAMA Netw Open. 2019;2(3):e190665.
15. Louisiana Opioid Surveillance Initiative. Bureau of Health Informatics. Louisiana Department of Health. Opioid Prescribing in Louisiana. Available at https://ldh.la.gov/assets/oph/Center-PHI/Opioid_Files/Opioid_Prescriptions_Fact_Sheet_2018.pdf. Last accessed August 12, 2022.
16. America's Health Rankings. Trend: Non-Medical Use of Prescription Opioids, United States. Available at https://www.americashealthrankings.org/explore/annual/measure/drug_use/population/drug_use_presc_opioids/state/ALL?edition-year=2020. Last accessed August 12, 2022.
17. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Washington, DC: Department of Veterans Affairs, Department of Defense; 2017.
18. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR. 2016;65(1):1-49.
19. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
20. Centers for Disease Control and Prevention. Process for Updating the Opioid prescribing Guideline. Available at https://www.cdc.gov/opioids/guideline-update/index.html. Last accessed August 12, 2022.
21. Federal Register. Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids. Available at https://www.federalregister.gov/documents/2022/02/10/2022-02802/proposed-2022-cdc-clinical-practice-guideline-for-prescribing-opioids. Last accessed August 12, 2022.
22. Centers for Disease Control and Prevention. Proposed 2022 CDC clinical practice guideline for prescribing opioids. Fed Register. 2022;87(28):7838-7840.
23. Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med. 2019;20(4):724-735.
24. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc. 2009;84(7):602-612.
25. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181-186.
26. National Comprehensive Cancer Network. Adult Cancer Pain, V2.2022. Available at https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Last accessed August 12, 2022.
27. U.S. Food and Drug Administration. Medication Guides: Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/media/79776/download. Last accessed August 12, 2022.
28. American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25(3):252-264.
29. Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148(2):141-146.
30. Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage. 2010;39(3):477-485.
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Palliative Care V 1.2022. Available athttps://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. Last accessed August 12, 2022.
32. Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage. 2008;35(6):594-603.
33. Blinderman CD, Homel P, Billings JA, Tennstedt S, Portenoy RK. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J Pain Symptom Manage. 2009;38(1):115-123.
34. Esther Kim J-E, Dodd MJ, Aouizerat BE, Jahan T, Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage. 2009;37(4):715-736.
35. Dalal S, Bruera E. Assessment and management of pain in the terminally ill. Prim Care Clin Office Pract. 2011;38:195-223.
36. Gao W, Gulliford M, Higginson IJ. Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10,202 lung cancer patients. Br J Cancer. 2011;104(11):1704-1710.
37. Godfrey C, Harrison MB, Medves J, Tranmer JE. The symptom of pain with heart failure: a systematic review. J Card Fail. 2006;12(4):307-313.
38. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29(36):4769-4775.
39. Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. 3rd ed. Baltimore, MD: Johns Hopkins University Press; 2014.
41. Zerzan J, Lee CA, Haverhals LM, Nowels CT. Exploring physician decisions about end-of-life opiate prescribing: a qualitative study. J Palliat Med. 2011;14(5):567-572.
42. Fineberg IC, Wenger NS, Brown-Saltzman K. Unrestricted opiate administration for pain and suffering at the end of life: knowledge and attitudes as barriers to care. J Palliat Med. 2006;9(4):873-883.
43. Mezei L, Murinson BB, Johns Hopkins Pain Curriculum Development Team. Pain education in North American medical schools.J Pain. 2011;12(12):1199-1208.
44. Dalal S, Bruera E. Assessment and management of pain in the terminally ill. Prim Care Clin Office Pract. 2011;38:195-223.
45. Desbiens NA, Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients? Crit Care Med. 2000;28(5):1347-1352.
46. Fishman B, Pasteranak S, Wallenstien SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer. 1987;60:1151-1158.
47. Stevans JM, Saper RB. Chronic low back pain. In: Rakel D (ed). Integrative Medicine. 3rd ed. Philadelphia, PA: Elsevier Inc.; 2012.
48. Berger AM, Shuster JL, Von Roenn JH (eds). Principles & Practice of Palliative Care & Supportive Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
49. Doyle D, Woodruff R. The IAHPC Manual of Palliative Care. 3rd ed. Houston, TX: International Association for Hospice and Palliative Care Press; 2013.
50. Adler ED, Goldfinger JZ, Park ME, Meier DE. Palliative care in the treatment of advanced heart failure. Circulation. 2009;120:2597-2606.
51. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med. 2009;23(2):103-110.
52. Utah Department of Health, Utah Medical Association. : 2018. Available at https://vipp.health.utah.gov/wp-content/uploads/Opioid-Clinical-Guidelines.pdf. Last accessed August 12, 2022.
53. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15(3 Suppl):S67-S116.
54. Webster LR. Eight Principles for Safe Opioid Prescribing. Paper presented at: American Academy of Pain Medicine Annual Meeting; April 2013; Fort Lauderdale, FL.
55. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442.
56. Opioid Risk Tool. Available at https://nida.nih.gov/sites/default/files/opioidrisktool.pdf. Last accessed August 12, 2022.
57. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.
58. Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1.0-SF. Available at https://www.mcstap.com/docs/SOAPP-5.pdf. Last accessed August 12, 2022.
59. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
60. Health Resources and Services Administration. CAGE-AID Substance Abuse Screening Tool. Available at https://www.hrsa.gov/behavioral-health/cage-aid-substance-abuse-screening-tool. Last accessed August 12, 2022.
61. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S16.
62. DIRE Score: Patient Selection for Chronic Opioid Analgesia. Available at https://amdg.wa.gov/Files/AssessmentTools/11-DIRE_score.pdf. Last accessed August 12, 2022.
63. Katz NP. Opioid Prescribing Toolkit: A Workbook for Clinicians. New York, NY: Oxford University Press; 2010.
64. Substance Abuse and Mental Health Services Administration. TIP 54: Managing Chronic Pain in Adults with or in Recovery From Substance Use Disorders. Available at https://www.samhsa.gov/resource/ebp/tip-54-managing-chronic-pain-adults-or-recovery-substance-use-disorders. Last accessed August 12, 2022.
65. American Chronic Pain Association. ACPA – Stanford Resource Guide to Chronic Pain Management: 2021 Edition. Available at https://med.stanford.edu/content/dam/sm/pain/documents/ACPA-Stanford-Resource-Guide-to-Chronic-Pain-Management-2021-Edition-4-18-21-.pdf. Last accessed August 12, 2022.
66. Strickland JM, Huskey A, Brushwood DB. Pharmacist-physician collaboration in pain management practice. J Opioid Manag. 2007;3:295-301.
68. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26:552-561.
69. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: an algorithmic, evidence-based approach. Pain Physician. 2012;15:ES177-ES189.
70. Baxter J. Minimizing the Misuse of Prescription Opioids in Patients with Chronic Nonmalignant Pain. Available at https://www.drugabuse.gov/nidamed/centers-excellence/resources/minimizing-misuse-prescription-opioids-in-patients-chronic-nonmalignant-pain. Last accessed August 12, 2022.
71. U.S. Drug Enforcement Administration. Prescriptions: Questions and Answers. Available at https://www.deadiversion.usdoj.gov/faq/prescriptions_faq.htm. Last accessed August 12, 2022.
72. Code of Federal Regulations. Title 21, Chapter II, Part 1306, General Information, §1306.05 Manner of Issuance of Prescriptions. Available at https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR1eb5bb3a23fddd0/section-1306.05. Last accessed August 12, 2022.
73. Code of Federal Regulations. Title 21, Chapter II, Part 1306, General Information, §1306.11 Requirement of Prescription. Available at https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR8588b52940237ef/section-1306.11. Last accessed August 12, 2022.
74. Schneider JP. Opioid prescribing part 2: appropriate documentation of follow-up visits. Practical Pain Management. 2014;14(2):36-39.
75. American College of Preventive Medicine. Use, Abuse, Misuse and Disposal of Prescription Pain Medication Time Tool. Available at https://cdn.ymaws.com/acpm.site-ym.com/resource/resmgr/timetools-files/painmedsclinicalreference.pdf. Last accessed August 12, 2022.
76. Office of National Drug Control Policy. Proper Disposal of Prescription Drugs. Available at https://www.ojp.gov/pdffiles1/ondcp/prescrip_disposal.pdf. Last accessed August 12, 2022.
77. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging. 2009;26(6):493-503.
78. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
79. Hughes CM, Cooper JA, Ryan C. Going beyond the numbers: a call to redefine polypharmacy. Br J Clin Pharmacol. 2014;77(6): 915-916.
80. Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. Cochrane Database Syst Rev. 2015;(5):e009235.
81. Atkinson TJ, Fudin J, Pandula A, Mirza M. Medication pain management in the elderly: unique and underutilized analgesic treatment options. Clin Ther. 2013;35(11):1669-1689.
82. American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
83. Lynch T. Management of drug-drug interactions: considerations for special populations: focus on opioid use in the elderly and long term care. Am J Manag Care. 2011;17(Suppl 11):S293-S298.
84. Budnitz D, Pollock D, Weidenbach K, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866.
85. Smith HS, Peppin JF. Toward a systematic approach to opioid rotation. J Pain Res. 2014;7:589-608.
86. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf. Last accessed August 12, 2022.
87. Berge KH, Dillon KR, Sikkink KM, Taylor TK, Lanier WL. Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention. Mayo Clin Proc. 2012;87(7):674-682.
88. Fan M, Tscheng D, Hamilton M, Hyland B, Reding R, Trbovich P. Diversion of controlled drugs in hospitals: a scoping review of contributors and safeguards. J Hosp Med. 2019;14(7):419-428.
89. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.
90. Meier B. Increase in Urine Testing Raises Ethical Questions. Available at https://www.nytimes.com/2013/08/02/business/increase-in-urine-testing-raises-ethical-questions.html?_r=0. Last accessed August 12, 2022.
91. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.
92. Holliday S, Hayes C, Dunlop A. Opioid use in chronic non-cancer pain. Part 2: prescribing issues and alternatives. Aust Fam Physician. 2013;42:104-111.
93. U.S. Department of Justice Office of Diversion Control. Don't Be Scammed By A Drug Abuser. Available at https://www.deadiversion.usdoj.gov/pubs/brochures/drugabuser.htm. Last accessed August 12, 2022.
94. American Medical Association. Code of Ethics: Opinion 1.1.5 Terminating the Patient-Physician Relationship. Available at https://www.ama-assn.org/system/files/code-of-medical-ethics-chapter-1.pdf. Last accessed August 12, 2022.
95. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. What Is a Prescriber's Role in Preventing the Diversion of Prescription Drugs? Available at https://www.cms.gov/files/document/drugdiversion022316pdf#. Last accessed August 12 2022.
96. Louisiana Administrative Code. Title 46: Professional and Occupational Standards. Part XLV: Medical Professions. Available at https://www.doa.la.gov/media/japawb11/46v45.pdf. Last accessed August 12, 2022.
97. Centers for Disease Control and Prevention. Risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.
98. Hannon K. The Prescription Drug Crisis in New York State: A Comprehensive Approach. Available at https://www.scribd.com/doc/82474334/Prescription-Drug-Abuse-Crisis-in-NYS-Comprehensive-Approach-New. Last accessed August 12, 2022.
99. U.S. Drug Enforcement Administration. Drug Scheduling. Available at https://www.dea.gov/drug-scheduling. Last accessed August 12, 2022.
100. U.S. Drug Enforcement Administration. Controlled Substance Schedules. Available at https://www.deadiversion.usdoj.gov/schedules. Last accessed August 12, 2022.
101. Louisiana Board of Medical Examiners. Information for CDS Prescribers RE: Act 76 of the 2017 Regular Session of the Louisiana Legislature. Available at https://a.storyblok.com/f/150540/3694d541d5/guidance-re-act-76.pdf. Last accessed August 12, 2022.
102. Louisiana State Legislature. Act No. 82. Available at http://www.legis.la.gov/legis/ViewDocument.aspx?d=1050996. Last accessed August 12, 2022.
103. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434-442.
104. U.S. Department of Justice. Drug Enforcement Administration. Diversion Control Division. ARCOS Retail Drug Summary Reports. Available at https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/. Last accessed August 12, 2022.
105. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). Available at https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set. Last accessed August 12, 2022.
106. Centers for Disease Control and Prevention. National Center for Health Statistics. Available at https://www.cdc.gov/nchs/nvss/deaths.htm. Last accessed August 12, 2022.
107. RADARS System. Available at https://www.radars.org/. Last accessed August 12, 2022.
108. Louisiana Board of Pharmacy. Prescription Monitoring Program (PMP) Information. Available at https://www.pharmacy.la.gov/page/prescription-monitoring-program-pmp-information. Last accessed August 12, 2022.
109. Epstein DH, Philips KA, Preston KL. Opioids. In: Ruiz P, Strain E (eds). Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011: 161-190.
110. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
111. Prince V. Pain management in patients with substance-use disorders. In: Chronic Illnesses I, II, and III– PSAP-VII, Book 5. Lenexa, KS: American College of Clinical Pharmacology; 2011.
112. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-care/definition-of-addiction. Last accessed August 12, 2022.
114. van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.
115. Kaye AD, Gevirtz C, Bosscher HA, et al. Ultrarapid opiate detoxification: a review. Can J Anaesth. 2003;50(7):663-671.
116. Xi ZX, Stein EA. GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol. 2002;37(5):485-494.
117. Harris AC, Gewirtz JC. Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal. Psychopharmacology (Berl). 2005;178(4):353-366.
118. National Institute on Drug Abuse. Screening and Assessment Tools Chart. Available at https://www.drugabuse.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools. Last accessed August 12, 2022.
119. National Institute on Drug Abuse. Tobacco, Alcohol, Prescription Medication, and Other Substance use Tool (TAPS). Available at https://nida.nih.gov/taps2/. Last accessed August 12, 2022.
120. Substance Abuse and Mental Health Services Administration. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Available at https://www.samhsa.gov/sbirt. Last accessed August 12, 2022.
121. Indian Health Service. Screening, Brief Intervention, and Referral to Treatment. Available at https://www.ihs.gov/asap/providers/sbirt/. Last accessed August 12, 2022.
122. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR. 2015;64(23);631-635.
123. Louisiana Department of Health. Standing Order for the Distribution or Dispensing of Naloxone or Other Opioid Antagonists. Available at https://ldh.la.gov/assets/HealthyLa/Pharmacy/NaloxoneStandingOrder.pdf. Last accessed August 12, 2022.
124. U.S. Department of Health and Human Services. Naloxone: The Opioid Reversal Drug That Saves Lives. Available at https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf. Last accessed August 12, 2022.
125. Gutstein HB, Akil H. Opioid analgesics. In: Brunton L, Parker K, Lazo J, Buxton I, Blumenthal D (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011: 547-590.
126. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed August 12, 2022.
127. Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80(2):189-200.
128. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3):277-288.
129. Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. HSS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
130. Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. HHS Publication No. (SMA) 16-4742. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
131. American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder, 2020 Focused Update. Available at https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline. Last accessed August 12, 2022.
132. Jain N, Chavan BS, Sidana A, Das S. Efficacy of buprenorphine and clonidine in opioid detoxification: a hospital-based study. Indian J Psychiatry. 2018;60(3):292-299.
133. Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):885-893.
134. U.S. Food and Drug Administration. FDA Approves the First Non-Opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults. Last accessed August 12, 2022.
135. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2008;(4):CD005031.
136. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011;9:CD005031.
137. Fiellin DA, O'Connor PG. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347(11):817-823.
138. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(1): 793-802.
139. Wasan AD, Correll DJ, Kissin I, O'Shea S, Jamison RN. Iatrogenic addiction in patients treated for acute or subacute pain: a systematic review. J Opioid Manag. 2006;2(1):16-22.
140. Heinzerling KG, Ober AJ, Lamp K, De Vries D, Watkins KE. SUMMIT: Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care. Available at https://www.rand.org/content/dam/rand/pubs/tools/TL100/TL148-1/RAND_TL148-1.pdf. Last accessed August 12, 2022.
141. Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol Tip 63. Available at https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf. Last accessed August 12, 2022.
142. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173-S177.
143. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207-225.
144. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021.
145. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303-2305.
146. Srivastava A. Primary care management of opioid use disorders. Can Fam Physician. 2017;63(3):200-205.
147. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Substance Abuse Treat. 2004;26(3):151-165.
148. Ronel N, Gueta K, Abramsohn Y, Caspi N, Adelson M. Can a 12-step program work in methadone maintenance treatment?Int J Offender Ther Comp Criminol. 2011;55(7):1135-1153.
149. Stoops WW, Lile JA, Glaser PE, Hays LR, Rush CR. Alternative reinforcer response cost impacts cocaine choice in humans.Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):189-193.
150. Donovan DM, Ingalsbe MH, Benbow J, Daley DC. 12-step interventions and mutual support programs for substance use disorders: an overview. Soc Work Public Health. 2013;28(3-4):313-332.
151. Jordan JB. Acupuncture treatment for opiate addiction: a systematic review. J Subst Abuse Treat. 2006;30(4):309-314.
152. Otto KC. Acupuncture and substance abuse: a synopsis, with indications for further research. Am J Addict. 2003;12(1):43-51.
153. Motlagh FE, Ibrahim F, Rashid RA, Seghatoleslam T, Habil H. Acupuncture therapy for drug addiction. Chin Med. 2016;11:16.
154. Wu SL, Leung AW, Yew DT. Acupuncture for detoxification in treatment of opioid addiction. East Asian Arch Psychiatry. 2016;26(2):70-76.
155. Dixon DW. Opioid Abuse Follow-Up. Prognosis. Available at https://emedicine.medscape.com/article/287790-followup#e4. Last accessed August 12, 2022.
157. National Institute on Drug Abuse. The Importance of Prevention in Addressing the Opioid Crisis. Available at https://www.drugabuse.gov/about-nida/noras-blog/2019/06/importance-prevention-in-addressing-opioid-crisis. Last accessed August 12, 2022.
1. Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). Pain Physician. 2017;20(2S):S111-S133. Available at https://www.painphysicianjournal.com/current/pdf?article=NDIwNA%3D%3D&journal=103. Last accessed August 25, 2022.
Mention of commercial products does not indicate endorsement.